Genomic landscape and treatment outcomes of CDKN2A/MTAP loss in NSCLC

Biallelic 9p21 loss defines a distinct NSCLC subset enriched in actionable drivers

BIOMARKER

CDKN2A

MTAP

Related cases

Visualization showing multiple rows of blue and orange squares, divided by a black dotted line.

Genomic and transcriptomic differences between early-onset and non-early-onset PDAC

Unable to determine image content.

Evaluating MTAP deletion and immune profile scores to identify unmet needs in solid tumors

Abstract grid of squares showing color gradients and clustered data points.

Shorter Pluvicto treatment course for patients with prostate cancer and high initial PSA